IP protection for pharmaceuticals
A growing and aging population is putting increased pressure on healthcare providers and innovators. Limited healthcare budgets are squeezing the value in the sector to innovators. It is therefore increasingly important that innovators obtain and defend a robust IP portfolio to protect their research and development assets. It is also crucial to monitor third-party rights that might disrupt the pharmaceutical value chain and clear the path where necessary.